O

Olema Oncology

Clinical-stage biopharma targeting ER-positive breast cancer

Medical Director - Clinical Development

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • A U.S. board-certified MD is required.
  • Board certification in Oncology, Hematology/Oncology, or a related specialty, with significant academic or industry experience.
  • At least 2 years of direct biotech or pharmaceutical experience in clinical development conducting clinical studies; a strong academic background may substitute.
  • Strong understanding of breast cancer treatment paradigms.
  • Experience designing and managing oncology clinical studies; experience as a principal investigator or academic breast cancer expert is valued.
  • Thorough understanding of the drug development process and ability to translate strategy into action, meet milestones, and adapt to change.
  • Strong knowledge of Good Clinical Practice, the U.S. Food and Drug Administration, and European Medicines Agency/Committee for Medicinal Products for Human Use regulations; familiarity with other global regulatory standards is advantageous.
  • Ability to operate effectively in a matrixed environment, influence without direct authority, and drive cross-functional alignment.
  • Ability to convey complex clinical data clearly to scientific and non-scientific audiences, verbally and in writing.
  • Demonstrated problem-solving ability, with urgency, focus, and creativity.
  • Record of participating in collaborative, high-performing teams and partnerships.
  • Ability to work in a highly organized, detail-oriented, and adaptable manner amid fast-changing priorities.
  • Thoughtful, decisive, and collaborative leadership that inspires confidence and trust.
  • Ability to connect complex information, anticipate downstream impacts, and translate strategy into action.
  • Ability to build credibility with internal teams and external stakeholders.
  • Relationship-building skills suited to a dynamic, mission-driven environment.
  • Commitment to continuous learning, professional growth, and developing others.

Responsibilities

  • Contribute to registration-enabling studies of palazestrant in combination with other therapies, including study design, regulatory engagement, and investigator collaboration.
  • Partner across functions to define and implement clinical development strategies and plans for multiple programs.
  • Serve as the medical expert and point of contact for clinical and scientific questions from internal and external stakeholders.
  • Participate in interactions with investigators, academic collaborators, thought leaders, and regulatory authorities.
  • Maintain clinical and scientific acumen through ongoing engagement with the oncology community and key scientific meetings.
  • Provide medical oversight and partner with contract research organizations for the palazestrant program, ensuring alignment with company values, standard operating procedures, and ethical standards.
  • Contribute to developing and executing clinical protocols, amendments, investigator brochures, study reports, abstracts, and manuscripts.
  • Ensure scientific rigor and data integrity with internal cross-functional teams, including Clinical Operations, Biostatistics, and Safety, and contract research organization teams.
  • Evaluate safety, pharmacology, and efficacy data from ongoing and completed studies to inform program strategy and decision-making.
  • Contribute to regulatory submissions and communications.
  • Collaborate with preclinical and translational scientists to develop and integrate biomarker strategies.
  • Support data generation, publication planning, and external communication of study results.

Desired Qualifications

  • Strong experience as a principal investigator or academic breast cancer expert.
  • Familiarity with global regulatory standards beyond Good Clinical Practice, the U.S. Food and Drug Administration, and European Medicines Agency/Committee for Medicinal Products for Human Use regulations.

About the Company

Olema Oncology

Clinical-stage biopharma targeting ER-positive breast cancer

Olema Oncology develops targeted therapies for women’s cancers, with a focus on ER-positive, HER2-negative breast cancer. Its lead drug, palazestrant (OP-1250), blocks and degrades the estrogen receptor (CERAN/SERD) to slow tumor growth, and a second program targets epigenetics with a KAT6 inhibitor in preclinical stages. The company is conducting a Phase 3 trial of palazestrant in combination with CDK4/6 inhibitors and has a collaboration with Novartis to test palazestrant with ribociclib and everolimus. Its goal is to bring palazestrant to market and advance the KAT6 program to clinical testing, expanding options for women with breast cancer.

Company size
51-200
Company stage
IPO
Headquarters
San Francisco, CA
Founded
2007

Recently Posted Jobs

Explore more opportunities at Olema Oncology

See more jobs